Viewing Study NCT00072969

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:54 PM
Ignite Modification Date: 2025-12-31 @ 8:40 PM
Study NCT ID: NCT00072969
Status: COMPLETED
Last Update Posted: 2008-03-04
First Post: 2003-11-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunosuppression View
None Myelodysplastic Syndrome View
None MDS View